GetTopicDetailResponse(id=ec6f6488874, topicName=泛發(fā)性膿皰型銀屑病, introduction=泛發(fā)性膿皰型銀屑病, content=null, image=null, comments=3, allHits=1747, url=https://h5.medsci.cn/topic?id=64888, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=80799, tagList=[TagDto(tagId=80799, tagName=泛發(fā)性膿皰型銀屑病)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2191561, encodeId=c73c21915619a, content=<a href='/topic/show?id=c564105082ba' target=_blank style='color:#2F92EE;'>#佩索利單抗#</a> <a href='/topic/show?id=ec6f6488874' target=_blank style='color:#2F92EE;'>#泛發(fā)性膿皰型銀屑病#</a>, objectTitle=中國速度！佩索利單抗家族皮下注射制劑率先在華獲批，用于減少12歲及以上青少年和成人的泛發(fā)性膿皰型銀屑病發(fā)作, objectType=article, longId=815998, objectId=f359815998d0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/evidence-based-medicine-wordcloud.jpg, objectUrl=/article/show_article.do?id=f359815998d0, replyNumber=0, likeNumber=77, createdTime=2024-03-06, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f359815998d0, moduleTitle=中國速度！佩索利單抗家族皮下注射制劑率先在華獲批，用于減少12歲及以上青少年和成人的泛發(fā)性膿皰型銀屑病發(fā)作, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f359815998d0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2163332, encodeId=d3b321633328c, content=<a href='/topic/show?id=6a6c10e0858f' target=_blank style='color:#2F92EE;'>#NPF#</a> <a href='/topic/show?id=ec6f6488874' target=_blank style='color:#2F92EE;'>#泛發(fā)性膿皰型銀屑病#</a> , objectTitle=2023 NPF共識聲明：泛發(fā)性膿皰型銀屑病, objectType=guider, longId=26625, objectId=381bf1c0033986af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=381bf1c0033986af, replyNumber=0, likeNumber=147, createdTime=2023-10-17, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=381bf1c0033986af, moduleTitle=2023 NPF共識聲明：泛發(fā)性膿皰型銀屑病, moduleType=guider, hrefUrl=http://ermita.cn/guideline/show_article.do?id=381bf1c0033986af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2106352, encodeId=745b210635244, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a><a href='/topic/show?id=456a966ee9' target=_blank style='color:#2F92EE;'>#IL-36R#</a>單抗<a href='/topic/show?id=c564105082ba' target=_blank style='color:#2F92EE;'>#佩索利單抗#</a><a href='/topic/show?id=4b3d104922f2' target=_blank style='color:#2F92EE;'>#spesolimab#</a>治療<a href='/topic/show?id=ec6f6488874' target=_blank style='color:#2F92EE;'>#泛發(fā)性膿皰型銀屑病#</a>, objectTitle=勃林格殷格翰IL-36R單抗spesolimab治療銀屑病在中國獲批, objectType=article, longId=752204, objectId=ab9be52204ef, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/b0bdc609c9394292ac843dcac3e87f70.jpg, objectUrl=/article/show_article.do?id=ab9be52204ef, replyNumber=0, likeNumber=139, createdTime=2022-12-16, rootId=0, userName=循證小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ab9be52204ef, moduleTitle=勃林格殷格翰IL-36R單抗spesolimab治療銀屑病在中國獲批, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ab9be52204ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1083983, encodeId=989f1083983c2, content=<a href='/topic/show?id=ec6f6488874' target=_blank style='color:#2F92EE;'>#泛發(fā)性膿皰型銀屑病#</a>勃林格殷格翰中國醫(yī)學(xué)和臨床研發(fā)負(fù)責(zé)人張維博士表示：“EffisayilTM 研究的結(jié)果非常令人鼓舞，表明spesolimab有望為GPP急性發(fā)作患者提供首個(gè)潛在療法，填補(bǔ)GPP治療領(lǐng)域的重大空白。我們已于今年10月在中國與全球同步遞交上市申請，期待它能早日獲批上市，為中國GPP患者帶來希望?！? objectTitle=泛發(fā)性膿皰型銀屑病, objectType=topic, longId=64888, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=90, createdTime=2021-12-24, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1)]
梅斯話題小助手
2020-05-29
前往app查看評論內(nèi)容
#泛發(fā)性膿皰型銀屑病#勃林格殷格翰中國醫(yī)學(xué)和臨床研發(fā)負(fù)責(zé)人張維博士表示：“EffisayilTM 研究的結(jié)果非常令人鼓舞，表明spesolimab有望為GPP急性發(fā)作患者提供首個(gè)潛在療法，填補(bǔ)GPP治療領(lǐng)域的重大空白。我們已于今年10月在中國與全球同步遞交上市申請，期待它能早日獲批上市，為中國GPP患者帶來希望?！?/span>
